Sort   by:  
 Page size 
MetabolomicsOxidative phosphorylation is a metabolic vulnerability of endocrine therapy and palbociclib resistant metastatic breast cancers
Resistance to endocrine treatments and CDK4/6 inhibitors is considered a near-inevitability in most patients with estrogen receptor positive breast cancers (ER + BC). By genomic and metabolomics analyses of patients' tumours, metastasis-derived patient-derived xenografts (PDX) and isogenic cell line...
2023-06-27 | MTBLS3342 | MetaboLights
TranscriptomicsRNA-seq of human breast cancer cell lines MCF7 and T74D naive and resistant to palbociclib treated with capivasertib, fulvestrant and combination
T47D and MCF7 cell lines were treated with long-term (continuous) palbociclib to induce 4 resistant cell-lines (T47D RB-, T47D CDK6H, MCF7 RB- and MCF7 PacqR). Each cell line (both parental and resistant) were then treated with DMSO (control), capivasertib monotherapy, fulvestrant monotherapy and ca...
ORGANISM(S): Homo sapiens 
2023-08-14 | E-MTAB-13262 | biostudies-arrayexpress
ProteomicsResistance to Palbociclib requires multiple targetable mechanisms highlighting the potential of drug holidays and drug switching to improve therapeutic outcome
Estrogen receptor positive (ER+) breast cancer is the most common type of breast cancer. Despite the great efficacy of endocrine therapies, resistance remains a problem. Therefore, there is an immediate need for new, effective therapies in ER+ BC. In this study, we have explored the role of a potent...
ORGANISM(S): Homo sapiens (Human) 
2020-03-25 | PXD005611 | Pride
Breast cancer Proteomics Resistance Palbociclib 
TranscriptomicsSingle cell RNA Seq to study the effects of Palbociclib in the mouse LSK cell compartment
To understand how Palbociclib (a CDK4/6 inhibitor) treatment changes the transcriptome of hematopoietic stem and progenitor cells, wildtype cells were isolated from mice and treated for 24h with either PBS (control) or Palbociclib. After 24h of culture, the cell suspensions were collected and sorted...
ORGANISM(S): Mus musculus 
2024-05-22 | E-MTAB-13268 | biostudies-arrayexpress
ProteomicsTUMOUR KINOME RE-WIRING GOVERNS RESISTANCE TO PALBOCICLIB IN OESTROGEN RECEPTOR POSITIVE BREAST CANCERS, HIGHLIGHTING NEW THERAPEUTIC MODALITIES
Estrogen receptor positive (ER+) breast cancers are the most common type of breast cancer. Despite the great efficacy of endocrine therapies, resistance remains a problem. Therefore, there is an immediate need for new, effective therapies in ER+ BC. In this study, we have explored the role of a pote...
ORGANISM(S): Homo sapiens (Human) 
2020-04-29 | PXD005514 | Pride
Breast cancer Resistance Palbociclib Phosphoproteomics 
ProteomicsProteomics analysis of Control and Palbociclib-treated HeLa cells
Liquid chromatography-tandem mass spectrometry (LC-MS/MS) was employed to profile the proteomes of Control and Palbociclib-treated HeLa cells. For protein identification and quantification, mass spectrometry data from fractionated samples (data-dependent acquisition, DDA; 6 fractions) and single-sho...
ORGANISM(S): Homo sapiens (Human) 
2025-12-04 | PXD070997 | Pride
Palbociclib，hela cells，lc-ms/ms 
TranscriptomicsHTG EdgeSeq analysis of parental and CDK4/6i-resistant (Ribociclib or Palbociclib) T47D breast cancer cell clones
Do illuminate the vulnerabilities of CDK4/6i-resistant T47D breast cancer cells, we created CDK4/6i-resistant T47D cell clones through a gradual dose escalation protocol using the selective CDK4/6 inhibitors Ribociclib and Palbociclib. We then performed gene expression analysis targeting 2549 genes ...
ORGANISM(S): Homo sapiens 
2026-06-17 | E-MTAB-15265 | biostudies-arrayexpress
ProteomicsPhospho-proteomic profile of control and Palbociclib-treated HeLa cells
Liquid Chromatography with tandem mass spectrometry (LC-MS/MS) identification of phosphorylation of control and Palbociclib-treated HeLa cells. For identification and quantification of protein, the single-shot subject samples (DIA MS data) were used to generate a direct-DIA library and computational...
ORGANISM(S): Homo sapiens (Human) 
2025-12-04 | PXD071048 | Pride
Phospho-proteomic profile，palbociclib，hela cells，lc-ms/ms 
GenomicsGene expression alterations associated with acquired-resistance to the CDK4/6 inhibitor palbociclib [Palbociclib resistance_RNASeq]
Gene expression alterations associated with acquired-resistance to the CDK4/6 inhibitor palbociclib [Palbociclib resistance_RNASeq]
PRJNA551944 | ENA
ProteomicsCDK4/6 inhibitor resistance in prostate cancer
CDK4/6 kinase inhibitors have shown great promise in clinical trials in various cancer types and have recently entered clinical trial for advanced prostate cancer. Although patients are expected to respond well to this class of drugs, development of resistance in some patients is anticipated. To pre...
ORGANISM(S): Homo sapiens (Human) 
2018-05-16 | PXD006561 | Pride
Palbociclib Lapc4 Ribociclib Cdk4/6 Prostate cancer Lncap 
Sort   by:  
 Page size